Trial Profile
To evaluate the safety of continuous Apixaban, Rivaroxaban and Dabigatran intake in patients undergoing cardiac implantable electronic device implantation in a real-world cohort
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists (Primary)
- Indications Thromboembolism
- Focus Adverse reactions
- 17 Sep 2018 New trial record
- 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology